Trial Profile
Value of Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Fertility-preserving Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Levonorgestrel (Primary) ; LHRH receptor agonists; Progesterone
- Indications Adenocarcinoma; Atypical endometrial hyperplasia; Endometrial cancer
- Focus Therapeutic Use
- 25 Jul 2020 Planned End Date changed from 31 Dec 2020 to 30 Dec 2030.
- 25 Jul 2020 Planned primary completion date changed from 30 Dec 2019 to 30 Dec 2025.
- 15 Mar 2018 New trial record